logo
CrowdStrike Stock Tumbles: Here's What Morgan Stanley Predicts Next

CrowdStrike Stock Tumbles: Here's What Morgan Stanley Predicts Next

CrowdStrike (NASDAQ:CRWD) stock had surged more than 40% year-to-date heading into its first fiscal quarter report, with its elevated valuation setting a high bar for performance. However, the results fell short, and shares tumbled ~6% in Wednesday's trading session.
Confident Investing Starts Here:
Revenue climbed 19.4% year-over-year to $1.1 billion but still fell $10 million short of Wall Street's expectations. According to management, subscription revenue took an $11 million hit, largely due to hurdles tied to Customer Commitment Packages (CCP), driven by one-off customer incentives and special partner programs. These headwinds aren't going away just yet – management expects a continued drag of $10 to $15 million per quarter over the next three periods. On a brighter note, the bottom line came through: adjusted EPS landed at $0.73, outpacing the Street's forecast by $0.07.
But the outlook also failed to please. For the current quarter, CrowdStrike sees revenue landing in the range between $1.145 billion and $1.152 billion, falling short of the $1.16 billion consensus estimate.
According to Morgan Stanley's Keith Weiss, the biggest sticking point wasn't the miss on revenue or guidance, but rather the net new annual recurring revenue (NNARR). Despite an 11% beat versus consensus – even better than the average ~8% beat seen over the past year – the figure didn't quite meet the buy-side's elevated hopes, especially with the stock trading at a steep 50x EV/CY27 free cash flow.
However, Weiss, who ranks among the top 2% of Street stock pros, believes that despite CrowdStrike being 'undeniably an expensive stock,' there's a compelling case for renewed 30%+ free cash flow growth. The company is gaining momentum as a 'leading consolidator' in the cybersecurity space, with nearly half its customers now using six or more modules and a strong uptake of Falcon Flex contracts, which have grown sixfold year-over-year. Demand remains solid, with generative AI expanding both the threat landscape and the need for advanced security tools – areas where CrowdStrike's Charlotte AI is seeing 'strong traction.' Finally, margins are trending higher, with Q1 operating margins beating expectations and management now guiding to over 30% FCF margins by fiscal 2027.
All told, Weiss sees enough upside to bump his price target from $455 to $490. Still, with shares already running hot, that implies just a modest 5% upside from current levels. Weiss' rating stays an Overweight (i.e., Buy). (To watch Weiss's track record, click here)
Elsewhere on the Street, the stock garners an additional 28 Buys, 8 Holds and 1 Sell, for a Moderate Buy consensus rating. However, the $471.06 average target implies the stock is currently fully valued. (See CrowdStrike stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)
Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)

Business Insider

time34 minutes ago

  • Business Insider

Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)

In a report released today, Edward Woo from Ascendiant maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report), with a price target of $7.50. The company's shares opened today at $0.87. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Woo covers the Healthcare sector, focusing on stocks such as GRI Bio, Envoy Medical, and Cingulate Inc. According to TipRanks, Woo has an average return of -8.2% and a 34.36% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atossa Therapeutics with a $5.56 average price target, a 539.08% upside from current levels. In a report released today, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $4.00 price target.

‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst
‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst

Business Insider

time34 minutes ago

  • Business Insider

‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst

Although Snowflake (SNOW) shares have already climbed over 35% this year, UBS believes that the software stock still has more room to grow. Following Snowflake's annual Summit in San Francisco, UBS upgraded the stock from Neutral to Buy and raised its price target from $210 to $265. Despite being late to the upgrade, analysts led by five-star rated Karl Keirstead said that Snowflake's performance has only started improving in the last few quarters, and that the broader AI-related investment cycle is just beginning. Confident Investing Starts Here: Indeed, UBS noted that Snowflake is one of the companies benefiting from the need for 'AI-ready' data, along with Palantir (PLTR) and Databricks. The analysts also pointed out that more software companies like Salesforce (CRM), ServiceNow (NOW), and SAP (SAP) are moving into the data space, which they see as evidence of the growing demand for data. As a result, UBS believes that Snowflake investors haven't fully priced in this growth potential yet and that there's still time to invest before the full AI boom happens. Separately, Morgan Stanley kept its Equal-weight rating and $200 price target despite Snowflake's strengths in data security, ease of use, and multi-cloud capabilities. While the analysts led by five-star rated Keith Weiss praised the company's role in secure AI integration, they remain cautious about the stock's high valuation, which sits at about 55 times the expected free cash flow for 2026. Nevertheless, it is worth mentioning that Snowflake's expansion into data engineering and AI has significantly increased its market opportunity and might justify its premium valuation. Is SNOW a Good Buy Right Now? Overall, analysts have a Strong Buy consensus rating on SNOW stock based on 34 Buys, six Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average SNOW price target of $225.03 per share implies 6.4% upside potential.

Wolfe Research Sticks to Its Buy Rating for Samsara (IOT)
Wolfe Research Sticks to Its Buy Rating for Samsara (IOT)

Business Insider

time34 minutes ago

  • Business Insider

Wolfe Research Sticks to Its Buy Rating for Samsara (IOT)

Wolfe Research analyst Alex Zukin maintained a Buy rating on Samsara (IOT – Research Report) today and set a price target of $45.00. The company's shares opened today at $42.75. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Zukin is a 5-star analyst with an average return of 19.1% and a 62.55% success rate. Zukin covers the Technology sector, focusing on stocks such as Salesforce, Okta, and Zscaler. In addition to Wolfe Research, Samsara also received a Buy from William Blair's Dylan Becker in a report issued today. However, on the same day, Truist Financial reiterated a Hold rating on Samsara (NYSE: IOT). The company has a one-year high of $61.90 and a one-year low of $27.14. Currently, Samsara has an average volume of 4.44M. Based on the recent corporate insider activity of 243 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IOT in relation to earlier this year. Most recently, in March 2025, James Andrew Munk, the CAO of IOT sold 9,369.00 shares for a total of $361,542.21.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store